Publication: 175

Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: Cancer and Leukemia group B (CALGB) 30106, a CALGB-stratified phase II trial.
      Google Scholar   
Citation:
J Thorac Oncol vol 5 (9) 1382-90
Year:
2010
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pub
Note:
Methodological:
No
Biospecimen:
No
SDC:
Yes
Book Volume:
Parents:
None
Children:
None
Program:
OGC
Primary Committee:
Respiratory
Sec. Committees:
   
Pharmas:
 
Grants:
 
Corr. Author:
 
Authors:
                     
Networks:
 
Study
CALGB-30106
Multiple Studies, or Legacy Studies in Alliance Study:
CALGB-150508
Phases:
2, N/A
Keywords:
Adenocarcinoma, Aged, Antineoplastic Combined Chemotherapy Protocols, Carboplatin, Carcinoma, Large Cell, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Combined Modality Therapy, Drug Resistance, Neoplasm, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Neoplasm Staging, Paclitaxel, Proto-Oncogene Proteins, Proto-Oncogene Proteins p21(ras), Quinazolines, Radiotherapy, Receptor, Epidermal Growth Factor, Survival Rate, Treatment Outcome, ras Proteins